Opinion: STAT+: China’s strict new supply chain regulations could create massive problems for Western biopharma companies

China is now a peer competitor in drug innovation — and it intends to stay that way on its own terms, writes Dennis Kwok.

More from STAT

Immigration changes are driving foreign researchers to leave the U.S. — or not come to begin with

STAT·6

Opinion: Are blue zones real? Answering that question is harder than ever

STAT·5

Federal appeals court blocks mailing of abortion pill mifepristone

STAT·9

Opinion: What do medical students think about their education?

STAT·10

Opinion: STAT readers on MAHA activists, perimenopause, and diversity in medical school

STAT·9

STAT+: Up and down the ladder: The latest comings and goings

STAT·12